Ganga Pharmaceuticals Ltd

Dematerialisation status

• RTA confirms dematerialisation of shares and cancellation of certificates.
• CDSL and NSDL confirm dematerialised and rematerialised details furnished to all stock exchanges.

MD Re-appointment

• Re-appointment of Bharat Brijmohan Sharma as MD for three years from April 01, 2026.
• Not liable to retire by rotation.
• Spouse of Srijna Sharma, Whole-time Director of the company.
• Profile: over 35 years in business and pharma industry.
• Not debarred from holding office by SEBI or other authorities.

AGM details

• AGM held on Sept 26, 2026 from 4:30–4:55 pm at the registered office (physical).
• Record date: Sept 18, 2026; total shareholders on record: 364.

Resolutions to vote

• Ordinary: adopt audited financial statements for year ended Mar 31, 2026.
• Ordinary: re-appoint Sanjay Kulkarni as Director by rotation.
• Ordinary: re-appoint Bharat Brijmohan Sharma as MD & CEO.

Voting results

• Resolution 1 passed with 100% in favour.
• Resolution 2 passed with 100% in favour.
• Resolution 3 passed with 100% in favour.

Directors / management changes

• Sanjay Kulkarni reappointed as Director (rotational).
• Bharat Brijmohan Sharma reappointed as MD & CEO.

Dividends / other approvals

• Dividend not declared or proposed.
• No material related party transactions or other material approvals reported.

Auditors

• No auditor appointments or changes disclosed.

Ganga Pharmaceuticals Limited — Trading Window closed from October 01, 2026 in connection with Un-audited Financial Results for the half year ending on September 30, 2026; The Trading Window will open 48 hours after the said financial results are declared to the Stock Exchange.

AGM Details

• AGM held on 26 Sep 2026 at 4:30 PM at the registered office.
• Meeting concluded at 4:55 PM IST.
• Mode: physical; remote e-voting 23-25 Sep 2026.

Resolutions

• Resolutions on ordinary and special business as per Notice (items 1-3).

Voting and Results

• Poll results not disclosed in this filing.

Directors and Attendance

• Attendance: Chairman, MD, WTD, and two Independent Directors.

Auditors

• Statutory Auditors represented; no appointment changes disclosed.

AGM and annual report access

• Discloses dispatch of AGM notice access links to shareholders with unregistered email addresses.
• Annual Report 2025-26 available online at the company website and BSE portal.
• AGM scheduled for Sep 26, 2026 at the registered office, 4:30 PM.
• Cut-off date for AGM attendance/entitlements: Sep 18, 2026.
• E-voting window opens Sep 23, 2026 9:00 AM; closes Sep 25, 2026 5:00 PM.
• Access instructions provided for Demat and physical mode shareholders.

AGM Details

• Date/time: 26 Sep 2026, 4:30 PM, at registered office.
• Mode: physical meeting.
• Cut-off date for voting: 18 Sep 2026.
• Remote e-voting: 23–25 Sep 2026.
• Register of Members close: 20–26 Sep 2026.

Ordinary Business

• Adopt Audited Financial Statements for year ended 31 Mar 2026.
• Re-appoint director retiring by rotation: Sanjay Kulkarni.

Special Business

• Re-appoint Bharat Brijmohan Sharma as MD & CEO for 3 years (Apr 1, 2026–Mar 31, 2029).
• Remuneration up to 21.6 lakh per annum; perquisites within Schedule V.
• No sitting fees for Board/Committees.
• Minimum remuneration in years of losses within statutory limits.
• Board authorized to execute documents and delegate powers.
• MD&CEO to continue as KMP and not retire by rotation.

Voting Status

• Voting results not provided in this filing.

Financial highlights

• Total income Rs 310.70 lakh, up from Rs 307.33 lakh.
• Revenue from operations Rs 282.79 lakh.
• PAT Rs 10.15 lakh; up from Rs 7.90 lakh.
• PBT Rs 12.93 lakh; up from Rs 9.47 lakh.
• Tax expense Rs 2.78 lakh.
• EPS basic and diluted Rs 0.17.
• No dividend declared; profits retained.
• End-year paid-up capital Rs 591.15 lakh after warrants.

Capital structure & liquidity

• Long-term borrowings Rs 9.81 lakh.
• Short-term borrowings Rs 99.19 lakh.
• Cash and equivalents Rs 5.82 lakh.
• Current assets Rs 756.45 lakh; current liabilities Rs 123.54 lakh.
• Market cap Rs 7.09 crore; P/E 0.17x.
• End-year paid-up capital Rs 591.15 lakh.

Dividends & reserves

• Dividend not declared for FY2025-26.
• Reserves & surplus Rs 240.11 lakh.
• Securities premium Rs 114.88 lakh.
• Profit retained in P&L Rs 100.74 lakh.

Operations & geography

• Core business: manufacturing and trading Ayurveda pharmaceuticals.
• Presence across Maharashtra, Karnataka, West Bengal, Orissa; expansion planned.
• Centralized manufacturing supports cost efficiency.
• Product distribution via major e-portals; improving market penetration.
• No subsidiary or joint venture; no major structural changes.

Governance & board

• Board of five: 2 exec, 1 non-exec chair, 2 independent.
• Audit, NRC, SRC committees active and independent.
• 7 board meetings; 5 Audit Committee meetings; 4 SRC; 3 NRC.
• Key KMP: MD Bharat Sharma; WTD Srijna Sharma; CFO Anagh Sharma.
• Secretarial audit conducted; no qualifications reported.

Audit, controls & compliance

• Statutory auditors Banka & Banka; no qualification.
• Internal financial controls are adequate and effective.
• Secretarial audit by D Maurya; no qualification.
• No material orders impacting going concern.

Remuneration & related party

• KMP remuneration 2025-26: MD 15.60; WTD 18.00; CFO 18.00; CS 2.25 lakh.
• Proposed MD remuneration: Rs 21.60 lakh per annum for 3 years.
• Remuneration within Section 197 Schedule V limits.
• Promoter: MD is a promoter; relatives noted in policy.
• Related party transactions are not material; AOC-2 not required.

Outlook & risks

• Ayurveda market growth driven by wellness demand and policy support.
• Regulatory, perception, and competition risks exist.
• Management targets profitability turnaround over 3-5 years.

Dematerialisation status

• Dematerialisation/rematerialisation requests processed within 15 days of receipt.
• Securities dematerialised/rematerialised listed on the exchanges where they are listed.
• Physical share certificates for dematerialisation mutilated and cancelled after verification.
• Depository's name substituted as registered owner for approved demat requests within the prescribed timeline.